EGFR Overexpression in Metaplastic Breast Carcinomas
Author Information
Author(s): Jorge S Reis-Filho, Fernanda Milanezi, Silvia Carvalho, Pete T Simpson, Dawn Steele, Kay Savage, Maryou Lambros, Emilio M Pereira, Jahn M Nesland, Sunil R Lakhani, Fernando C Schmitt
Primary Institution: The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
Hypothesis
Do metaplastic breast carcinomas exhibit HER2 and EGFR overexpression and gene amplification?
Conclusion
Metaplastic breast carcinomas frequently overexpress EGFR, which is associated with EGFR gene amplification in one-third of cases.
Supporting Evidence
- 76% of metaplastic breast carcinomas exhibited EGFR overexpression.
- 37% of cases with EGFR overexpression showed gene amplification.
- No HER2 gene amplification was detected in the studied cases.
Takeaway
This study found that many metaplastic breast cancers have a lot of a protein called EGFR, which might help doctors find new treatments for these cancers.
Methodology
Twenty-five metaplastic breast carcinomas were analyzed using immunohistochemistry and chromogenic in situ hybridization for EGFR and HER2.
Limitations
The study had a small sample size and limited follow-up data.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website